Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal diseaseStatus:In developmentProgramme:NICE guidelineExpected publication date: 29 June 2022
Type 1 diabetes in adults: diagnosis and management – periodontal diseaseStatus:In developmentProgramme:NICE guidelineExpected publication date: 29 June 2022
Type 2 diabetes in adults: management - periodontal diseaseStatus:In developmentProgramme:NICE guidelineExpected publication date: 29 June 2022
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 6 June 2022Expected publication date: 14 September 2022
Brolucizumab for treating diabetic macular oedema [ID3902]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 November 2022
Diabetic foot problems: prevention and management (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 18 January 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 3 January 2024
Diabetic retinopathyStatus:In developmentProgramme:NICE guidelineExpected publication date: 3 April 2024
Diabetic retinopathy - ruboxistaurin [ID382]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Diabetes - buccal insulin [ID311]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Faricimab for treating diabetic macular oedema [ID3899]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes ID3938Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesStatus:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Type 2 diabetes in adults: management (medicines update)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC